Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 96% 0.04 [0.00-0.68] death 0/1,039 12/1,046 Improvement, RR [CI] Treatment Control Pfizer (DB RCT) 70% 0.30 [0.08-1.08] hosp. 3/428 10/426 Tau​2 = 0.76, I​2 = 37.8%, p = 0.049 Early treatment 83% 0.17 [0.03-0.99] 3/1,467 22/1,472 83% improvement All studies 83% 0.17 [0.03-0.99] 3/1,467 22/1,472 83% improvement 2 paxlovid COVID-19 studies c19early.com/pl Jan 17, 2022 Tau​2 = 0.76, I​2 = 37.8%, p = 0.049 Effect extraction pre-specified Favors paxlovid Favors control
Paxlovid COVID-19 studies. PAXLOVID™ is an investigational SARS-CoV-2 protease inhibitor antiviral therapy combining PF-07321332 and ritonavir. Paxlovid has been officially adopted for early treatment in 1 country. Submit updates/corrections.
Dec 14
Early Pfizer Press Release (News)
hosp., ↓70.1%, p=0.05
Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk or hospitalization or death
Details   EPIC-SR trial interim results, 428 patients treated with paxlovid (PF-07321332 + ritonavir) and 426 control patients, showing lower hospitalization with treatment. NCT05011513.
Nov 30
In Vitro Ullrich et al., bioRxiv, doi:10.1101/2021.11.28.4702264 (Preprint) (In Vitro)
In Vitro
Main protease mutants of SARS-CoV-2 variants remain susceptible to PF-07321332
Details   In Vitro study showing that PF-07321332 maintains efficacy against variants C.37 lambda, B.1.1.318, B.1.2, B.1.351 beta, and P.2 zeta.
Nov 5
Animal Abdelnabi et al., bioRxiv, doi:10.1101/2021.11.04.467077 (Preprint)
animal study
The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
Details   In Vitro and hamster study showing paxlovid component PF-07321332 effective against four variants of concern, inibits replication of the alpha variant in primary human airway epithelial cells, protected Syrian hamsters against intranasal ..
Nov 5
Early Pfizer Press Release (interim results 11/5/2021) (News)
death, ↓96.0%, p=0.0005
Pfizer's novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study
Details   EPIC-HR trial, 1039 higher risk patients treated with paxlovid (PF-07321332 + ritonavir) and 1046 control patients, showing significantly lower mortality and hospitalization with treatment. NCT04960202.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit